IVAX Diagnostics Announces PARSEC™ System Order from Henry Ford Health System, the Leading Integrated Healthcare Network in Detroit

Business Wire, Oct 6, 2005

MIAMI -- IVAX Diagnostics, Inc. (AMEX:IVD) announced that its wholly-owned subsidiary, Diamedix Corporation in Miami, Florida, has received a purchase order from Henry Ford Health System for an expanded PARSEC(TM) System. This new five-module automation system is expected to replace current instrumentation and streamline much of the ELISA testing performed by Henry Ford Health System's microbiology and serology-virology laboratories. Henry Ford Health System, one of the country's largest health care systems, integrates primary and specialty care with research and education. It includes six owned or affiliated hospitals, a 540,000-member health maintenance organization, 22 primary care centers and many other health-related entities located throughout southeastern Michigan.

John T. Waugh, Henry Ford's Director of System Laboratory Operations, said, "Henry Ford is committed to providing exceptional care to our patients in a cost-effective manner. We are leveraging new technology, information systems, and the talent of our staff to make this happen. After an extensive review of all options, we are pleased with our decision to purchase a Diamedix PARSEC(TM) System to improve the throughput and efficiency of ELISA testing that we perform. We are also excited about the modular design and ability to add additional technology in the future, such as chemiluminescence testing."

Giorgio D'Urso, CEO and president of IVAX Diagnostics, said, "We are pleased to have Henry Ford Health System as one of our premier customers for the PARSEC(TM) System. We have designed this new laboratory automation platform to be flexible and scalable and the pathology laboratory at Henry Ford Health System has been able to take advantage of this architecture by customizing a PARSEC(TM) System to best meet their specific laboratory testing needs. Henry Ford Health System is a large and prestigious medical facility and the five-module system that they have ordered is the largest PARSEC(TM) System configuration that has been purchased to date. We look forward to working closely with Henry Ford Health System in the future."

About IVAX Diagnostics, Inc.

IVAX Diagnostics, Inc., headquartered in Miami, Florida, develops, manufactures and markets proprietary diagnostic reagents, instrumentation and software in the United States and Italy through its three subsidiaries: Diamedix Corporation, Delta Biologicals S.r.l., and ImmunoVision, Inc. IVAX Corporation (AMEX:IVX) (LSE:IVX.L) owns approximately 74% of IVAX Diagnostics, Inc. For more information about IVAX Diagnostics, please visit our web site at http://www.ivaxdiagnostics.com.

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of IVAX Diagnostics, Inc., including, without limitation: risks and uncertainties regarding the PARSEC(TM) System, including, without limitation, that the PARSEC(TM) System may not be available when or perform as expected, that the PARSEC(TM) System may not permit laboratories to increase their throughput efficiency when performing testing or otherwise streamline their testing, and that additional technology such as chemiluminescence testing may not be available on the PARSEC(TM) System in the future; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in IVAX Diagnostics' filings with the Securities and Exchange Commission.